Beyond the Abstract: Applying New Evidence to PROC Practice–A Rapid-Response Interactive Journal Club Featuring Practice-Relevant Data Emerging From ESMO

The treatment landscape for platinum-resistant ovarian cancer (PROC) is rapidly evolving, with new therapeutic options, biomarker-directed strategies, and emerging clinical evidence introducing greater complexity into treatment selection and sequencing. Clinicians must navigate differences in trial populations, biomarker eligibility, prior treatment exposure, and safety profiles while determining how new findings apply to individual patients. Despite these advances, significant educational gaps persist in critically evaluating emerging evidence, incorporating newer therapies into clinical practice, and making evidence-informed treatment decisions. The presentation of new data at ESMO 2026 further underscores the need for timely education to help clinicians distinguish practice-changing findings from investigational approaches and translate evolving evidence into personalized care.

In this interactive, enduring Journal Club, expert faculty will examine key PROC findings from ESMO 2026, providing practical guidance on interpreting clinical trial results, evaluating biomarker and treatment eligibility, and individualizing therapeutic selection and sequencing based on prior treatments, toxicity considerations, and patient preferences. Through embedded expert commentary, interactive learning moments, case-based polling, and downloadable clinical decision tools, learners will gain actionable insights to confidently integrate emerging evidence into real-world treatment decisions.

At the conclusion of this activity, learners will be able to better:

• Evaluate late-breaking and recently published PROC evidence according to trial design, patient population, biomarker strategy, efficacy/safety endpoints, and evidence maturity
• Select individualized treatment and sequencing strategies for PROC based on biomarker profile, prior therapies, toxicity considerations, and patient priorities

This activity is supported by an independent educational grant from Genmab US, Inc.

Gynecologic oncologists, medical oncologists, nurse practitioners (NPs), physician associates (PAs), oncology nurses and pharmacists

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Lee reports the following financial relationships:

Advisory Board: AstraZeneca; Daiichi Sankyo Company; Genmab A/S; GSK; and Oncusp Therapeutics

Research Support: (paid to my institution): Accent Therapeutics, Inc.; Cogent Biosciences, Inc.; Debiopharm International SA; Genmab A/S; GSK; Merck & Co., Inc.; Nikang Therapeutics, Inc.; and OnCusp Therapeutics, Inc.

Dr. O’Malley reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; BeOne Medicines Ltd; Corcept Therapeutics; Duality Biologics; Daiichi Sankyo, Inc.; Genmab A/S; GOG Foundation, Inc.; GSK plc; Lilly; Merck & Co., Inc.; Merck Sharp & Dohme LLC; Novocure; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Verastem, Inc.; and Zentalis

Consultant: AbbVie Inc.; AstraZeneca; BeOne Medicines Ltd; Corcept Therapeutics; Duality Biologics; Daiichi Sankyo, Inc.; Genmab A/S; GOG Foundation, Inc.; GSK plc; Lilly; Merck & Co., Inc.; Merck Sharp & Dohme LLC; Novocure; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Verastem, Inc.; and Zentalis

Grants: AbbVie Inc.; Advaxis/Ayala Pharmaceuticals, Inc.; Agenus Inc.; Alkermes plc; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeOne Medicines Ltd; Boston Biomedical, Inc.; Bristol Myers Squibb; Clovis Oncology, Inc.; Deciphera Pharmaceuticals, Inc.; Eisai Co., Ltd.; EMD Serono, Inc.; Exelixis; Genentech, Inc.; Genmab A/S; GSK plc; GOG Foundation Inc.; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc.; Incyte Corporation; IOVANCE Biotherapeutics, Inc.; Karyopharm Therapeutics, Inc.; Leap Therapeutics, Inc.; Ludwig Institute for Cancer Research; Merck & Co., Inc.; Merck Sharp & Dohme LLC; Mersana Therapeutics, Inc.; Novartis AG; Novocure Limited; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc.; Precision Therapeutics, Inc.; Prelude Therapeutics Incorporated; Regeneron Pharmaceuticals, Inc.; Radiation Therapy Oncology Group; Rubius Therapeutics, Inc.; Seagen Inc.; Sutro Biopharma, Inc.; SWOG Cancer; TESARO, inc.; and Verastem, Inc.

Research Support: AbbVie Inc.; Advaxis/Ayala Pharmaceuticals, Inc.; Agenus Inc.; Alkermes plc ; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeOne Medicines Ltd; Boston Biomedical, Inc.; Bristol Myers Squibb; Clovis Oncology, Inc.; Deciphera Pharmaceuticals, Inc.; Eisai Co., Ltd.; EMD Serono, Inc.; Exelixis; Genentech, Inc.; Genmab A/S; GSK plc; GOG Foundation Inc.; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc.; Incyte Corporation; IOVANCE Biotherapeutics, Inc.; Karyopharm therapeutics, Inc.; Leap Therapeutics, Inc. Ludwig Institute for Cancer Research; Merck & Co., Inc.; Merck Sharp & Dohme LLC; Mersana Therapeutics, Inc.; Novartis AG; Novocure Limited; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc.; Precision Therapeutics, Inc.; Prelude Therapeutics Incorporated; Regeneron Pharmaceuticals, Inc.; Radiation Therapy Oncology Group; Rubius Therapeutics, Inc.; Seagen Inc.; Sutro Biopharma, Inc.; SWOG Cancer; TESARO, inc.; and Verastem, Inc.

Other financial or material support: DSMB: Amarex Clinical Research, LLC / Frantz Viral Therapeutics, LLC

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Thomas Mitchell, MSW, LSW (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.